Literature DB >> 31567588

Mohs Micrographic Surgery as the Standard of Care for Nail Unit Squamous Cell Carcinoma.

Darlene Gou1, Rajiv I Nijhawan, Divya Srivastava2.   

Abstract

BACKGROUND: There is no established standard of care for treatment of nail unit squamous cell carcinoma (SCC).
OBJECTIVE: The aim of the study is to further characterize the clinical characteristics and diagnostic considerations of nail unit SCC and to examine the outcomes of patients with nail unit SCC treated with Mohs micrographic surgery (MMS).
MATERIALS AND METHODS: A retrospective review was conducted of patients treated for nail unit SCC with MMS from January 1, 2006, to December 30, 2016. Demographic data were collected along with lesion characteristics, treatment characteristics, and follow-up results.
RESULTS: Forty-two cases of nail unit SCC were treated with MMS. Recurrences were observed in 3 patients (7.1%). Recurrent cases were treated with MMS. There were no cases of distant metastases, subsequent recurrence, or death. Two of 3 recurrences occurred in patients with histologic features of verruca vulgaris.
CONCLUSION: Mohs micrographic surgery provides an excellent cure rate for the treatment of nail unit SCC. This technique offers the greatest ability to achieve histological clearance while maximizing tissue sparing, thereby reducing unnecessary amputations and patient morbidity.

Entities:  

Mesh:

Year:  2020        PMID: 31567588     DOI: 10.1097/DSS.0000000000002144

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  2 in total

1.  Clinical Treatment Study of Secondary Multiple Squamous Cell Carcinoma with Psoriasis Vulgaris.

Authors:  Sai-Nan Han; Shi-Jun Feng; Dong-Fang Ai
Journal:  J Oncol       Date:  2022-01-06       Impact factor: 4.375

2.  Atypical parakeratosis in nail unit squamous cell carcinoma.

Authors:  Aman Prasad; Bridget E Shields; Yaohui G Xu; Juliet L Aylward; Molly A Hinshaw
Journal:  J Cutan Pathol       Date:  2022-04-25       Impact factor: 1.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.